Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Lilly/Daiichi Sankyo’s Migraine Med Reyvow Hits Japan Market
June 9, 2022
- Eisai Ups Earnings Guidance for FY2022
June 9, 2022
- Idorsia Japan Set to File Its 2nd and 3rd Drugs Early Next Year, Eyes 80 Billion Yen Sales in 5 Years
June 9, 2022
- Horizon Taps Yoshihide Okino as VP and Japan GM
June 8, 2022
- Novartis Sees CML Med Scemblix as Growth Driver over Next Decade, 1st Line Use Holds Key
June 8, 2022
- Japan Ethical Drug Sales Slip 1.9% in April: Crecon
June 8, 2022
- Daiichi Sankyo’s HER3-Directed ADC Shows Promise in Breast Cancer
June 7, 2022
- Enhertu Delivers Stellar PIII Data in HER2 Low Breast Cancer
June 7, 2022
- Kissei Launches MPA/GPA Med Tavneos in Japan
June 7, 2022
- Opdivo Grabs Japan Sales Crown for 5 Months Running in May: Encise
June 7, 2022
- FoundationOne Gets Nod as CDx for 4 Drugs: Chugai
June 6, 2022
- FDA to Review Myfembree for Long-Term Use in Uterine Fibroids
June 6, 2022
- Sanofi’s Sakigake-Tagged ASMD Drug Hits Japan Market
June 6, 2022
- Chugai Eyes Continuous Production of Investigational Biologics by Late 2020s: Executive
June 6, 2022
- Keytruda Most Promoted Drug via In-Hospital Seminars for 1st Time in April: Intage
June 6, 2022
- Bayer Rolls Out CKD Drug Kerendia in Japan
June 3, 2022
- Gilead Japan Eyes High-Single-Digit Annual Growth with Oncology as Third Biz Pillar
June 3, 2022
- Japan’s Medical Big Data Market to Top 700 Billion Yen in 2035: Fuji Keizai
June 3, 2022
- Astellas, US-Based GO to Codevelop New Immuno-Oncology Antibodies
June 2, 2022
- Fujifilm Kicks Off US PIIa Study for Liposome Cancer Drug in Combo with Keytruda
June 2, 2022
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…